Shanghai Heartcare Medical Technology Corp. Ltd. Class H (HK:6609)
:6609
Top Page
Shanghai Heartcare Medical Technology Corp. Ltd. Class H
(6609)
Select Model
Select Model
Rating:61Neutral
Price Target:
HK$53.00
▼(-2.93% Downside)
Action:ReiteratedDate:01/22/26
The score is primarily supported by improving business fundamentals (revenue growth and strong gross margin) and a very strong balance sheet with low leverage. This is tempered by mixed profitability/cash-flow quality signals (negative EBIT margin and modest OCF coverage) and a demanding valuation (P/E 42.22), while technicals are moderately positive but not strongly accelerating.
Positive Factors
High Gross Margin
A sustained gross margin near 67.5% indicates strong product pricing, differentiated device/software offerings, and efficient production. Over 2–6 months this margin buffer supports reinvestment in R&D, absorbs SG&A, and underpins durable profitability as sales scale in cardiovascular devices.
Negative Factors
Negative EBIT Margin
A negative EBIT margin implies operating costs (R&D, sales, or admin) outpace core operating earnings. If maintained, it threatens long-term operating profitability and requires either sustained margin improvement or continued external funding to support growth in the capital‑intensive medtech sector.
Read all positive and negative factors
Positive Factors
Negative Factors
High Gross Margin
A sustained gross margin near 67.5% indicates strong product pricing, differentiated device/software offerings, and efficient production. Over 2–6 months this margin buffer supports reinvestment in R&D, absorbs SG&A, and underpins durable profitability as sales scale in cardiovascular devices.
Read all positive factors
Shanghai Heartcare Medical Technology Corp. Ltd. Class H (6609) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$1.87B
Dividend YieldN/A
Average Volume (3M)127.28K
Price to Earnings (P/E)22.4
Beta (1Y)1.29
Revenue Growth32.93%
EPS GrowthN/A
CountryHK
Employees344
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)0.93
Shares Outstanding31,565,804
10 Day Avg. Volume119,990
30 Day Avg. Volume127,280
Financial Highlights & Ratios
PEG Ratio0.67
Price to Book (P/B)0.73
Price to Sales (P/S)2.80
P/FCF Ratio-92.80
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)2.69
Revenue Forecast (FY)HK$539.68M
Shanghai Heartcare Medical Technology Corp. Ltd. Class H Business Overview & Revenue Model
Company Description
Shanghai HeartCare Medical Technology Corporation Limited engages in the research, development, manufacture, and sale of neuro-interventional medical devices worldwide. The company offers ischemic stroke thrombectomy, intracranial stenosis treatme...
How the Company Makes Money
Shanghai Heartcare Medical Technology Corp. Ltd. generates revenue through multiple streams, primarily by selling its proprietary medical devices and diagnostic equipment to hospitals, clinics, and healthcare providers. The company also earns mone...
Shanghai Heartcare Medical Technology Corp. Ltd. Class H Financial Statement Overview
Summary
Income Statement
65
Positive
Balance Sheet
70
Positive
Cash Flow
60
Neutral
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 334.94M | 277.90M | 232.34M | 183.03M | 90.09M | 14.56M |
| Gross Profit | 226.03M | 181.72M | 151.79M | 124.33M | 54.95M | 7.09M |
| EBITDA | 22.90M | 21.87M | -68.50M | -167.31M | -183.34M | -206.19M |
| Net Income | 42.44M | -13.62M | -94.01M | -200.38M | -194.22M | -213.66M |
Balance Sheet | ||||||
| Total Assets | 1.25B | 1.21B | 1.20B | 1.31B | 1.50B | 773.63M |
| Cash, Cash Equivalents and Short-Term Investments | 718.20M | 713.72M | 721.14M | 870.12M | 1.22B | 632.42M |
| Total Debt | 45.91M | 35.75M | 36.38M | 50.69M | 41.94M | 24.69M |
| Total Liabilities | 137.78M | 144.00M | 125.60M | 147.08M | 132.10M | 82.60M |
| Stockholders Equity | 1.11B | 1.06B | 1.08B | 1.17B | 1.37B | 681.37M |
Cash Flow | ||||||
| Free Cash Flow | 30.56M | -8.39M | -137.72M | -304.01M | -260.33M | -90.42M |
| Operating Cash Flow | 41.60M | -3.23M | -88.41M | -266.77M | -205.85M | -74.81M |
| Investing Cash Flow | -194.07M | 10.80M | -125.45M | 44.84M | -161.10M | -4.53M |
| Financing Cash Flow | -11.15M | -12.38M | -21.48M | -24.75M | 821.25M | 686.22M |
Shanghai Heartcare Medical Technology Corp. Ltd. Class H Technical Analysis
Positive
54.60
Price Trends
47.13
Positive
49.11
Negative
51.17
Negative
Market Momentum
0.12
Negative
58.85
Neutral
78.95
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6609, the sentiment is Positive. The current price of 54.6 is above the 20-day moving average (MA) of 45.08, above the 50-day MA of 47.13, and above the 200-day MA of 51.17, indicating a neutral trend. The MACD of 0.12 indicates Negative momentum. The RSI at 58.85 is Neutral, neither overbought nor oversold. The STOCH value of 78.95 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:6609.
Shanghai Heartcare Medical Technology Corp. Ltd. Class H Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | HK$1.87B | 22.44 | 4.25% | ― | 32.93% | ― | |
57 Neutral | HK$7.86B | 36.52 | 1.98% | ― | 3.42% | -70.82% | |
53 Neutral | HK$965.82M | -1.91 | -30.05% | ― | -8.56% | -14.84% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | HK$4.12B | -6.84 | -11.27% | ― | 29.25% | 9.02% | |
44 Neutral | HK$3.12B | -495.98 | -1.35% | ― | 49.86% | 80.35% | |
43 Neutral | HK$3.69B | -218.71 | 0.22% | ― | -4.38% | ― |
* Healthcare Sector Average
HK:6609
Shanghai Heartcare Medical Technology Corp. Ltd. Class H
48.16
20.96
77.06%
HK:9996
Peijia Medical Ltd.
6.14
1.72
38.91%
HK:1302
LifeTech Scientific Corporation
1.82
0.48
35.82%
HK:2160
MicroPort CardioFlow Medtech Corp.
2.90
-0.90
-23.68%
HK:2235
MicroTech Medical (Hangzhou) Co., Ltd. Class H
7.40
1.35
22.31%
HK:2500
Venus Medtech (Hangzhou), Inc. Class H
2.19
0.25
12.89%
Shanghai Heartcare Medical Technology Corp. Ltd. Class H Corporate Events
Shanghai HeartCare’s Novel Intracranial Drug-Eluting Stent Application Accepted by China’s NMPA
Jan 20, 2026
Shanghai HeartCare Medical Technology Corporation Limited has announced that China’s National Medical Products Administration has accepted the registration application for its self-expanding intracranial drug-eluting stent, designed to treat...
Shanghai HeartCare Signals Strong 2025 Turnaround With Positive Profit Alert
Jan 20, 2026
Shanghai HeartCare Medical Technology Corporation Limited has issued a positive profit alert, indicating that its 2025 revenue is expected to rise to about RMB400–410 million, at least 43.9% higher than 2024, and that it anticipates a profit...
Shanghai HeartCare Reports Shareholder Turnout and Voting Base for 2026 First EGM and Class Meetings
Jan 16, 2026
Shanghai HeartCare Medical Technology Corporation Limited held its 2026 first extraordinary general meeting (EGM), along with separate class meetings for H shareholders and unlisted shareholders, on 16 January 2026 in Shanghai, with all directors ...
Shanghai HeartCare Medical Technology Sets January 16, 2026 Date for Extraordinary and Class Shareholder Meetings
Jan 15, 2026
Shanghai HeartCare Medical Technology Corporation Limited has reminded shareholders of its upcoming extraordinary general meeting and separate class meetings for H shareholders and unlisted shareholders, all scheduled to start at 10:00 a.m. on Fri...
Shanghai HeartCare Calls 2026 Class Meeting to Approve Non-Pre-Emptive Domestic Share Issuance
Dec 31, 2025
Shanghai HeartCare Medical Technology Corporation Limited has convened a 2026 class meeting of its unlisted shareholders on 16 January 2026 in Shanghai to seek approval for a proposed issuance of new domestic shares under a specific mandate. Share...
Shanghai HeartCare Calls 2026 Extraordinary Meeting to Revamp Governance and Approve New Share Issue
Dec 31, 2025
Shanghai HeartCare Medical Technology Corporation Limited has called its first extraordinary general meeting of 2026 for 16 January in Shanghai, where shareholders will vote on a series of governance, capital and structural measures. The agenda in...
Shanghai HeartCare Calls H Shareholders’ Meeting to Approve Domestic Share Issuance Plan
Dec 31, 2025
Shanghai HeartCare Medical Technology Corporation Limited has convened a 2026 first class meeting of its H shareholders to be held in Shanghai on 16 January 2026, immediately after an extraordinary general meeting, to vote on several key capital-r...
Shanghai HeartCare Sets January Meetings on Share Issuance and Articles Changes
Dec 29, 2025
Shanghai HeartCare Medical Technology Corporation Limited has scheduled an extraordinary general meeting and a class meeting of H shareholders for 16 January 2026 to consider, among other matters, the proposed issuance of domestic shares under a s...
Shanghai Heartcare Revamps Share Incentive Program to Boost Efficiency
Dec 15, 2025
Shanghai Heartcare Medical Technology Corp. Ltd. announced a change in its share incentive program by canceling previously granted share awards and issuing new ones. This move is aimed at motivating management personnel to maximize their efforts f...
Shanghai Heartcare Proposes Issuance of Domestic Shares to Boost Competitiveness
Dec 12, 2025
Shanghai Heartcare Medical Technology Corp. Ltd. has announced a proposed issuance of 1,000,000 domestic shares under a specific mandate, priced at HK$45.00 each, as part of a subscription agreement with Mr. Zhang. This move aims to enhance the co...
Shanghai HeartCare Proposes Governance Changes Amid New Regulatory Landscape
Dec 12, 2025
Shanghai HeartCare Medical Technology Corporation Limited has announced its intention to abolish its Supervisory Committee in favor of establishing an Audit Committee, in compliance with the new amendments to the Company Law of the People’s ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.